Channel Partnerships US BIOLOGIC's LymeShield System and oral wildlife vaccines present clear channels for partnerships with pest management firms, veterinary networks, wildlife programs, and livestock operations. The May 2024 collaboration with JP McHale Pest Management demonstrates channel viability and provides a blueprint for co-development and distribution deals that can accelerate market access for preventive vaccines.

One Health Opportunity Products target wildlife, companion animals, food animals, and humans, aligning with One Health trends and preventive disease strategies. This creates sales opportunities with public health agencies, veterinary clinics, wildlife agencies, and livestock producers seeking cross-species disease prevention solutions.

Regulatory Support Edge US BIOLOGIC offers funding, regulatory support, manufacturing, and distribution expertise to bring products to market. This capability is attractive to partners with R&D but limited commercialization resources, enabling faster product launches and broader distribution for LymeShield and future vaccines.

Market Momentum Recent launches and collaborations, including the LymeShield System and BARDA DRIVe engagement in prior years, indicate a proven path from development to market. This momentum can be leveraged to pitch co-development, licensing, or contract manufacturing opportunities to distributors, veterinary brands, and public health buyers.

Distribution Growth Potential With a modest team and revenue scope, US BIOLOGIC could scale through strategic distributors, mid-market veterinary and animal health players, and government programs seeking preventive vaccines. Targeting ecosystems where Lyme disease and tick-borne disease are priorities can expand revenue through enhanced distribution and expanded product lines.